Neuroepithelioma  >>  Imlygic (talimogene laherparepvec)  >>  Phase 3
Welcome,         Profile    Billing    Logout  

3 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Imlygic (talimogene laherparepvec) / Amgen
NCT02147951: Expanded Access Protocol of Talimogene Laherparepvec for Subjects With Unresected, Stage lllB to IVM1c Melanoma

No Longer Available
3b
US
Talimogene Laherparepvec
Amgen
Unresected Stage IIIb to IVM1c Melanoma
 
 
OPTiM, NCT00769704: Efficacy and Safety Study of Talimogene Laherparepvec Compared to Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) in Melanoma

Checkmark From OPTIM study
May 2015 - May 2015: From OPTIM study
Checkmark SSO 2015
Mar 2015 - Mar 2015: SSO 2015
Checkmark For melanoma
More
Completed
3
437
US, Canada, Europe, RoW
Talimogene laherparepvec, OncoVEX^GM-CSF, IMLYGIC™, GM-CSF, Leukine, Sargramostim
BioVex Limited, Amgen
Melanoma
02/13
09/14
NCT01368276 / 2010-021070-11: An Extended Use Study of Safety and Efficacy of Talimogene Laherparepvec in Melanoma

Checkmark ESMO 2014
Sep 2014 - Sep 2014: ESMO 2014
Completed
3
31
US, Europe
Talimogene Laherparepvec, OncoVEX^GM-CSF, IMLYGIC™, Granulocyte Macrophage Colony-Stimulating Factor (GM-CSF)
BioVex Limited
Melanoma
09/14
09/14

Download Options